These findings suggest that the prognosis of patients with pretreatment detection of NF1 mutation in the PALOMA- phase III trial191 could overcome the risk of early relapse via the investigation in an adjuvant setting in NF1-mutant cancers of combined fulvestrant and palbociclib192. The gene discussed is NF1; the disease is cancer.